Prompted by the discovery of the JAK2V617F gain-of-function mutation in more than 50 % of patients with PMF or ET and at least 95 % of patients with PV [4], the importance of JAK–STAT pathway dysregulation in the pathogenesis of MPNs is now well established [5]. This evidence concerns the gene SOAT1 and essential thrombocythemia.